The Vetr crowd upgraded their rating for Celgene Corporation (NASDAQ: CELG) from 4.5 stars (Buy), issued two days ago, to 5 stars (Strong). Crowd sentiment is generally positive, with 66 percent of Vetr user ratings bullish.
Coming on the heels of the annual American Society of Hematology conference (ASH). Clelgene's announcements at ASH included promising results in several early studies investigating a treatment for blood cell-inhibiting syndromes such as lukemia.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Late in November, the biopharma company also received a nod from Oppenheimer, who initiated coverage of the stock at Outperform.
See how crowdsourced ratings could help you time the market.
Currently, Vetr's average crowd users target price for the stock is up at $131.21, which is below the average analyst target price of $138.36. Less than 2 percent of Vetr users are holding T in their watch lists.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.